Medexus Pharmaceuticals Inc
TSX:MDP
Medexus Pharmaceuticals Inc
TSX:MDP
Price:
3.5
CAD
6.71%
Market Closed
Market Cap:
CA$113.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Medexus Pharmaceuticals Inc
TSX:MDP
|
CA |
|
J
|
Johnson Electric Holdings Ltd
OTC:JELCF
|
HK |
|
Luokung Technology Corp
NASDAQ:LKCO
|
CN |
|
Nomura Real Estate Holdings Inc
TSE:3231
|
JP |
|
Arena Bilgisayar Sanayi ve Ticaret AS
IST:ARENA.E
|
TR |
|
Pacific Biosciences of California Inc
NASDAQ:PACB
|
US |
|
Bank Aladin Syariah Tbk PT
IDX:BANK
|
ID |
|
I
|
Ion Exchange (India) Ltd
NSE:IONEXCHANG
|
IN |
|
Synergie SE
PAR:SDG
|
FR |
|
S
|
Senseonics Holdings Inc
AMEX:SENS
|
US |
|
N
|
NBTM New Materials Group Co Ltd
SSE:600114
|
CN |
|
Software AG
XETRA:SOW
|
DE |
|
C
|
Century Global Commodities Corp
TSX:CNT
|
HK |
|
Abm International Ltd
NSE:ABMINTLLTD
|
IN |
|
Lakshmi Machine Works Ltd
NSE:LAXMIMACH
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
MDP
stock under the Base Case scenario is
hidden
CAD.
Compared to the current market price of 3.5 CAD,
Medexus Pharmaceuticals Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MDP Multiples-Based Value
LOCKED
Multiples Across Competitors
MDP Competitors Multiples
Medexus Pharmaceuticals Inc Competitors
Medexus Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Medexus Pharmaceuticals Inc
TSX:MDP
|
113.1m CAD | 0.8 | -303.5 | 6.3 | 22 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
